Please login to the form below
NovoSeven
This page shows the latest NovoSeven news and features for those working in and with pharma, biotech and healthcare.
EMA clears Novo Nordisk’s long-acting haemophilia A drug
That is a positive for Novo Nordisk’s overall haemophilia franchise which is being hit by declining sales of factor VII replacement product NovoSeven, but there’s little doubt that the
Latest news
-
First blood to Roche in Hemlibra patent fight with Shire
The haemophilia A with inhibitors category is currently dominated by Shire and Novo Nordisk with its Feiba and NovoSeven bypassing agents (PBAs).
-
Roche gets first approval for haemophilia A therapy
The market for haemophilia A with inhibitors is currently dominated by Shire and Novo Nordisk with their Feiba and NovoSeven bypassing agents (PBAs).
-
Shire wins block of Roche' 'misinformation' over emicizumab
The market for haemophilia A with inhibitors is currently dominated by Shire and Novo Nordisk with their Feiba and NovoSeven bypassing agents (PBAs).
-
Patient death mars Roche haemophilia drug trial
for breakthrough bleeds which includes Shire's Feiba and Novo Nordisk's NovoSeven. ... Analysts have previously suggested that emicizumab could attack around half the revenues of NovoSeven, which made sales of almost $1.4bn in 2016, and eat into the
-
Novo Nordisk wins US approval for haemophilia treatment
The drug will be used in conjunction with Novo's MixPro, the pre-filled device that was launched earlier this year and is already in use with the company's NovoSeven ... Novo's existing haemophilia A and B treatment for patients with inhibitors, NovoSeven
More from news
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Novo Nordisk awakens its ‘Sleeping Beauty’
His confidence is underpinned by more launches being inked into the Biopharm calendar, along with recent European approval for a bolus delivery system for its NovoSeven haemophilia product. ... For years physicians were asking us for NovoSeven to be used
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Trials resume for AZ/Oxford University COVID-19 vaccine
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Moderna inks R&D agreements with Vertex and Chiesi
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
- Route 66: can remote working put two-thirds of us back on the road to engaged employment?
- Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Quick links
Infographics
